Stocks
PDL Biopharma IncPDLI
HealthcareBiotechnology
A biopharmaceutical company that acquires and manages royalty assets, primarily from commercial-stage drugs. Its portfolio generates recurring revenue through licensing agreements, and investors track it for its dividend history and asset monetization strategies.
Congressional Interest in PDL Biopharma Inc (PDLI)
3 members of Congress have disclosed 4 trades in PDL Biopharma Inc (PDLI), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 3 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
4
Unique Politicians
3
Buys
1
Sells
3
Who in Congress Is Trading PDLI?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2017-03-21 | Thomas R Carper | sell | $1K-$15K |
| 2016-07-14 | Thomas R Carper | sell | $1K-$15K |
| 2015-07-14 | JAMES B. RENACCI | buy | $1K-$15K |
| 2010-03-08 | MICHAEL T. MCCAUL | sell | $1K-$15K |